NRG-GI008: Colon Adjuvent Chemotherapy Based on Evaluation of Residual Disease (Circulate-US)
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal cancer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 855020
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
